Literature DB >> 25769055

Antipsychotic prescribing: do conflict of interest policies make a difference?

Timothy S Anderson1, Haiden A Huskamp, Andrew J Epstein, Colleen L Barry, Aiju Men, Ernst R Berndt, Marcela Horvitz-Lennon, Sharon-Lise Normand, Julie M Donohue.   

Abstract

BACKGROUND: Academic medical centers (AMCs) have increasingly adopted conflict of interest policies governing physician-industry relationships; it is unclear how policies impact prescribing.
OBJECTIVES: To determine whether 9 American Association of Medical Colleges (AAMC)-recommended policies influence psychiatrists' antipsychotic prescribing and compare prescribing between academic and nonacademic psychiatrists. RESEARCH
DESIGN: We measured number of prescriptions for 10 heavily promoted and 9 newly introduced/reformulated antipsychotics between 2008 and 2011 among 2464 academic psychiatrists at 101 AMCs and 11,201 nonacademic psychiatrists. We measured AMC compliance with 9 AAMC recommendations. Difference-in-difference analyses compared changes in antipsychotic prescribing between 2008 and 2011 among psychiatrists in AMCs compliant with ≥ 7/9 recommendations, those whose institutions had lesser compliance, and nonacademic psychiatrists.
RESULTS: Ten centers were AAMC compliant in 2008, 30 attained compliance by 2011, and 61 were never compliant. Share of prescriptions for heavily promoted antipsychotics was stable and comparable between academic and nonacademic psychiatrists (63.0%-65.8% in 2008 and 62.7%-64.4% in 2011). Psychiatrists in AAMC-compliant centers were slightly less likely to prescribe these antipsychotics compared with those in never-compliant centers (relative odds ratio, 0.95; 95% CI, 0.94-0.97; P < 0.0001). Share of prescriptions for new/reformulated antipsychotics grew from 5.3% in 2008 to 11.1% in 2011. Psychiatrists in AAMC-compliant centers actually increased prescribing of new/reformulated antipsychotics relative to those in never-compliant centers (relative odds ratio, 1.39; 95% CI, 1.35-1.44; P < 0.0001), a relative increase of 1.1% in probability.
CONCLUSIONS: Psychiatrists exposed to strict conflict of interest policies prescribed heavily promoted antipsychotics at rates similar to academic psychiatrists and nonacademic psychiatrists exposed to less strict or no policies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25769055      PMCID: PMC4360919          DOI: 10.1097/MLR.0000000000000329

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  27 in total

1.  Promotion of prescription drugs to consumers.

Authors:  Meredith B Rosenthal; Ernst R Berndt; Julie M Donohue; Richard G Frank; Arnold M Epstein
Journal:  N Engl J Med       Date:  2002-02-14       Impact factor: 91.245

2.  A social science perspective on gifts to physicians from industry.

Authors:  Jason Dana; George Loewenstein
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

3.  Factors in choosing atypical antipsychotics: toward understanding the bases of physicians' prescribing decisions.

Authors:  Jennifer Hoblyn; Art Noda; Jerome A Yesavage; John O Brooks; Javaid Sheikh; Tina Lee; Jared R Tinklenberg; Bret Schneider; Ruth O'Hara; Douglas L Leslie; Robert A Rosenheck; Helena C Kraemer
Journal:  J Psychiatr Res       Date:  2005-09-08       Impact factor: 4.791

4.  Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression.

Authors:  Julie M Donohue; Ernst R Berndt; Meredith Rosenthal; Arnold M Epstein; Richard G Frank
Journal:  Med Care       Date:  2004-12       Impact factor: 2.983

5.  Psychiatric decision making in the adoption of a new antipsychotic in Germany.

Authors:  Johannes Hamann; Susanne Adjan; Stefan Leucht; Werner Kissling
Journal:  Psychiatr Serv       Date:  2006-05       Impact factor: 3.084

6.  First- and second-generation antipsychotics: learning from CUtLASS and CATIE.

Authors:  Rajiv Tandon; William T Carpenter; John M Davis
Journal:  Arch Gen Psychiatry       Date:  2007-08

7.  Has the hunt for conflicts of interest gone too far? Yes.

Authors:  Thomas P Stossel
Journal:  BMJ       Date:  2008-03-01

8.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Authors:  Peter B Jones; Thomas R E Barnes; Linda Davies; Graham Dunn; Helen Lloyd; Karen P Hayhurst; Robin M Murray; Alison Markwick; Shôn W Lewis
Journal:  Arch Gen Psychiatry       Date:  2006-10

9.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

10.  A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors.

Authors:  Sebastian Schneeweiss; Robert J Glynn; Jerry Avorn; Daniel H Solomon
Journal:  J Clin Epidemiol       Date:  2005-01       Impact factor: 6.437

View more
  4 in total

1.  Orthopaedic Surgeons Receive the Most Industry Payments to Physicians but Large Disparities are Seen in Sunshine Act Data.

Authors:  Andre M Samuel; Matthew L Webb; Adam M Lukasiewicz; Daniel D Bohl; Bryce A Basques; Glenn S Russo; Vinay K Rathi; Jonathan N Grauer
Journal:  Clin Orthop Relat Res       Date:  2015-06-19       Impact factor: 4.176

2.  The Impact Of Academic Medical Center Policies Restricting Direct-To-Physician Marketing On Opioid Prescribing.

Authors:  Matthew D Eisenberg; Elizabeth M Stone; Harlan Pittell; Emma E McGinty
Journal:  Health Aff (Millwood)       Date:  2020-06       Impact factor: 6.301

3.  Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing.

Authors:  Ian Larkin; Desmond Ang; Jonathan Steinhart; Matthew Chao; Mark Patterson; Sunita Sah; Tina Wu; Michael Schoenbaum; David Hutchins; Troyen Brennan; George Loewenstein
Journal:  JAMA       Date:  2017-05-02       Impact factor: 56.272

4.  Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review.

Authors:  Kristina Medlinskiene; Justine Tomlinson; Iuri Marques; Sue Richardson; Katherine Stirling; Duncan Petty
Journal:  BMC Health Serv Res       Date:  2021-11-05       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.